[1] Yu S, Ueda K, Chan P. Alpha-synuclein and dopamine metabolism[J]. Mol Neurobiol, 2005, 31(1-3):243-254. [2] Aarsland D, Creese B, Politis M, et al. Cognitive decline in Parkinson disease[J]. Nat Rev Neurol, 2017, 13(4):217-231. [3] Horak M, Holubova K, Nepovimova E,et al. The pharmacology of tacrine at N-methyl-d-aspartate receptors[J]. Prog Neuropsychopharmacol Biol Psychiatry,2017, 75:54-62. [4] Hall H, Reyes S, Landeck N,et al. Hippocampal Lewy pathology and cholinergic dysfunction are associated with dementia in Parkinson's disease[J]. Brain, 2014, 137(Pt 9):2493-2508. [5] Ullman M T, Pullman M Y. A compensatory role for declarative memory in neurodevelopmental disorders[J]. Neurosci Biobehav Rev, 2015, 51:205-222. [6] Foster T C, Kyritsopoulos C, Kumar A. Central role for NMDA receptors in redox mediated impairment of synaptic function during aging and Alzheimer's disease[J]. Behav Brain Res, 2017, 322(Pt B):223-232. [7] Cheng F, Li X, Li Y,et al. alpha-Synuclein promotes clathrin-mediated NMDA receptor endocytosis and attenuates NMDA-induced dopaminergic cell death[J]. J Neurochem, 2011, 119(4):815-825. [8] Arnett A L, Bayazitov I, Blaabjergm, et al. Antisense oligonucleotide against GTPase Rab5b inhibits metabotropic agonist DHPG-induced neuroprotection[J]. Brain Res, 2004,1028(1):59-65. [9] 王鹏, 李昕, 陈予东, 等. α-突触核蛋白寡聚体抑制大鼠原代培养神经元突起早期生长[J]. 首都医科大学学报, 2014, 35(5):587-591. [10] Wu H Y, Yuen E Y, Lu Y F,et al. Regulation of N-methyl-D-aspartate receptors by calpain in cortical neurons[J]. J Biol Chem, 2005, 280(22):21588-21593. [11] Yin J, Han J, Zhang C,et al. C-terminal part of alpha-synuclein mediates its activity in promoting proliferation of dopaminergic cells[J]. J Neural Transm (Vienna),2011, 118(8):1155-1164. |